Peer Trading Multiples for IPO Pricing: EV/Revenue vs EV/EBITDA

Introduction

Selecting the right trading multiple is the central judgment call in every IPO valuation. ECM bankers have a small set of standard multiples (EV/Revenue, EV/EBITDA, P/E, plus a handful of sector-specific metrics) and a recognizable framework for which one anchors the analysis based on the issuer's stage, sector, and growth profile. The choice is not arbitrary: applying EV/EBITDA to a pre-profit SaaS issuer would produce no meaningful number (EBITDA is negative), while applying EV/Revenue to a mature financial services business would discard the meaningful earnings information the market actually prices. A pre-IPO SaaS company at 30 percent growth and 15 percent EBITDA margin gets anchored on EV/Revenue against a Rule of 40 cohort; a regional bank at the same size gets P/E plus price-to-book; a midstream energy carve-out gets EV/EBITDA cross-checked against EV-per-flowing-barrel. The selection is the first non-trivial decision in any IPO valuation, and getting it wrong is the kind of error that surfaces immediately in investor pushback during the bookbuild.

Enterprise value over revenue is the dominant multiple for pre-profit and early-profit growth issuers, where the underlying business has not yet scaled to meaningful EBITDA but is investing aggressively in growth.

When to Use It

EV/Revenue is the right anchor when the issuer's revenue is growing at meaningful rates (typically 20+ percent annually) and EBITDA is either negative or unrepresentative of the steady-state business. Pre-IPO SaaS companies, growth-stage biotech with revenue but no profits, AI infrastructure providers (CoreWeave, Lambda Labs), consumer growth platforms, and many fintech issuers default to EV/Revenue because the multiple captures the business's scale and growth without forcing meaningless earnings comparisons.

The Rule of 40 Framework

For software issuers, the Rule of 40 is the principal multiple-driver:

where $g_{\text{revenue}}$ is the revenue growth percentage and $m_{\text{EBITDA}}$ the EBITDA margin percentage. A SaaS issuer with 30 percent revenue growth and 15 percent EBITDA margin has a Rule of 40 score of 45, qualifying as a premium SaaS profile. In Q4 2025, each 10-point improvement in Rule of 40 was associated with approximately 1.1x of additional EV/Revenue multiple expansion. The framework lets ECM bankers compare SaaS issuers across different growth-margin combinations on a common scale.

Rule of 40

The dominant SaaS valuation framework adding revenue growth percentage to EBITDA margin percentage to produce a single quality score. SaaS issuers scoring above 40 are considered premium-quality and typically command EV/Revenue multiples of 8x or higher; issuers scoring 20 to 40 trade at 4 to 7x revenue; issuers scoring below 20 trade at 1 to 3x revenue. Each 10-point improvement in Rule of 40 was associated with roughly 1.1x of additional EV/Revenue multiple expansion in Q4 2025, up from 0.8x earlier in the year, reflecting investor focus on operational efficiency alongside growth.

Typical EV/Revenue Levels

Public software companies in 2025 trade at approximately 5.1x EV/Revenue at the index level, with significant dispersion based on the Rule of 40 score: companies scoring under 20 trade at 1 to 3x revenue, those scoring 20 to 40 at 4 to 7x revenue, and those scoring over 40 can command 8 to 15x revenue or more. Median EV/ARR clusters near 6x in 2025 with a typical range of 3 to 10x depending on growth, retention, and gross margin.

The 2021-2025 Multiple Compression

The 2021 SaaS peak (median 18.6x EV/Revenue across the public universe) is gone. The 2022-2023 correction compressed multiples by over 60 percent, and 2025 levels remain near the 2015-2016 baseline of 6 to 7x EV/Revenue at the index. The companies commanding even those reduced multiples look very different from the 2021 cohort: slower median growth rates (12-15 percent versus the 30+ percent typical at the peak), higher profitability expectations, and increasing investor emphasis on the Rule of 40 over pure revenue growth. As of Q4 2025, only about 20 percent of the 58 actively-traded public SaaS companies exceed the Rule of 40 threshold, with median scores near 28.

Growth-Cohort EV/ARR Bands

ECM bankers segment SaaS issuers into growth cohorts that anchor different multiple ranges. Early-stage SaaS at 100+ percent year-over-year growth trades 10 to 15x ARR; mid-growth SaaS at 50 to 100 percent growth trades 7 to 10x ARR; mature SaaS at 20 to 50 percent growth settles at 5 to 8x ARR. Net revenue retention (NRR) also drives material variation: NRR below 90 percent corresponds to roughly 1.2x revenue, NRR of 100-110 percent to roughly 6x, NRR above 120 percent to 8x or higher. The cohort framework is what lets bankers position a specific issuer relative to the public universe with discipline.

Enterprise value over EBITDA is the right anchor for established profitable issuers where the business has scaled to meaningful EBITDA and the market prices on the bottom-line cash-generation profile.

When to Use It

EV/EBITDA is the dominant multiple for software at scale (large established SaaS players where the business has matured), most industrials and manufacturing (where capital intensity makes D&A relevant), consumer products and retail (with stable margin profiles), healthcare services (excluding biotech), and most middle-market businesses across sectors. The multiple's appeal is that it captures cash-generation capacity while abstracting from capital structure (so debt-financed and equity-financed peers compare cleanly).

The 2025 Software Inflection

A notable 2025 shift is that EV/EBITDA multiples have become increasingly relevant for SaaS issuers as the sector has matured: the SaaS index trades at approximately 26.6x EBITDA in aggregate, which is broadly in line with traditional economy businesses on a like-for-like growth basis. Disclosed private SaaS deals with positive EBITDA frequently clear above 20x EV/EBITDA, and the multiple's relevance has expanded as more SaaS businesses cross into profitability with EBITDA margins of 9 to 15 percent.

Industrial and Consumer Conventions

Industrial issuers typically value at EV/EBITDA in the 8 to 12x range, with capital-intensive sub-sectors (specialty chemicals, defense electronics, building products) at the higher end. Consumer issuers value at EV/EBITDA in the 10 to 18x range, with branded consumer goods and food at the higher end and commodity consumer products at the lower end. The typical anchor multiple for established industrial and consumer IPOs is EV/EBITDA cross-checked against EV/Revenue and P/E.

Price-to-earnings is the right anchor for mature businesses with stable earnings where the equity market explicitly prices earnings rather than EBITDA or revenue.

When to Use It

P/E is the dominant multiple for financial services (banks, insurance, asset managers), REITs (cross-checked with FFO and AFFO multiples), utilities, and mature stable-earnings industrials. The financial-services anchor is structural: banks' EBITDA is not a meaningful concept (interest expense is part of operating cash flow), so the equity market prices on net income directly. P/E also handles dividend-paying mature businesses cleanly because the market prices earnings yield.

Typical P/E Levels

Bank P/E levels in 2025 cluster at 10 to 14x for established US regional and money-center banks, 12 to 18x for insurance carriers depending on business mix, and 12 to 20x for asset managers depending on AUM growth and product mix. Mature industrial issuers price at P/E levels of 18 to 25x, with the specific level driven by growth and margin profile. Mature consumer issuers price at 18 to 30x P/E.

The PEG Cross-Check

For cross-sector P/E comparisons where growth rates differ materially, the PEG ratio normalizes the P/E by the issuer's expected earnings growth rate:

PEG values around 1.0 are typically considered fairly priced; below 1.0 implies growth not fully reflected in the multiple; above 1.0 implies the market is paying up for growth. PEG is most useful as a sanity check across issuers with different growth profiles, less so as a primary anchor.

Biotech valuation departs from the standard multiple framework because most pre-IPO biotechs have no revenue (research-stage) or limited revenue (clinical-stage commercial launch).

Risk-Adjusted Net Present Value

Pre-revenue biotechs are typically valued through risk-adjusted NPV (rNPV): each pipeline candidate is modeled with peak sales, royalty rates, time to commercialization, and probability of regulatory and clinical success at each phase. The rNPV sums the probability-weighted discounted cash flows across all candidates plus the cash and platform value. Biotech ECM bankers spend most of their valuation time building rNPV models rather than applying trading multiples directly.

Risk-Adjusted Net Present Value (rNPV)

A biotech-specific valuation methodology that models each pipeline candidate's expected cash flows weighted by the probability of regulatory and clinical success at each development phase. rNPV models include peak sales estimates, royalty rates, time-to-commercialization assumptions, and probability adjustments at each clinical trial phase (Phase I to Phase III) and at FDA approval. The rNPV sums probability-weighted discounted cash flows across all candidates plus cash and platform value. rNPV is the dominant pre-revenue biotech valuation methodology because traditional multiples cannot apply.

When Trading Multiples Apply to Biotech

For biotechs with established commercial revenue (typically post-launch products generating $100 million+ annual revenue), trading multiples on EV/Revenue or P/E come back into play. The transition typically happens 12 to 24 months post-commercial launch, when the issuer has enough operating history to support standard multiple analysis. Until that point, the trading multiples on commercial-stage biotech peers are useful only as reference points rather than direct anchors.

Even with the right multiple selected, the issuer's specific profile typically warrants adjustments to the applied multiple relative to the peer median.

Premium Adjustments

Issuers warrant premium multiples (above peer median) for higher growth than the peer set, higher gross or EBITDA margins, larger TAM with longer growth runway, stronger competitive moats (network effects, switching costs, scale economies), better unit economics (LTV/CAC, retention metrics, capital efficiency), or more durable competitive position. The premium magnitude depends on the dimension and severity: a SaaS issuer with 10 percentage points higher Rule of 40 than the peer set might warrant 1 to 2 turns of additional EV/Revenue multiple.

Discount Adjustments

Issuers warrant discount multiples (below peer median) for lower growth than the peer set, customer or geographic concentration, weaker margin profile, governance concerns (dual-class share structures, controlling shareholders, related-party transactions), regulatory uncertainty in the issuer's market, or first-time public-company status without operating history. Discount magnitudes typically run 10 to 30 percent below peer median for issuers with multiple adverse adjustments.

Bridging the Gap to the Peer Median

ECM bankers spend significant time articulating the specific factors that justify the issuer's positioning relative to the peer set. The narrative around premium and discount adjustments is itself part of the marketing of the IPO, and well-prepared issuers walk the IPO investor base through their relative positioning during the roadshow explicitly.

Beyond the general framework, several sectors use specialized metrics that ECM bankers covering those sectors use as primary or co-primary anchors.

Banks: P/E Plus P/B

Banks are typically valued on both P/E and price-to-book (P/B). P/B reflects the bank's capital base and is the cleaner metric for comparing capital-adequacy and book-value-driven institutions; large US money-center banks trade at 1.0 to 1.5x P/B with regional and specialty banks at 0.8 to 2.0x depending on growth and ROE. The combined P/E plus P/B framework captures both the earnings trajectory and the capital base, and bank IPO valuations require both.

Insurance: P/E Plus P/B Plus Embedded Value

Life insurance issuers add embedded value (the present value of future profits from in-force policies) as a third anchor. Property and casualty insurers value primarily on P/E and combined-ratio benchmarks. Reinsurance issuers value on tangible book value adjusted for catastrophe exposures.

REITs: P/AFFO Plus NAV

REITs value on price-to-adjusted-funds-from-operations (P/AFFO, similar to P/E for REITs) plus net asset value (NAV) calculated from the property portfolio's market value. P/AFFO multiples cluster at 12 to 20x for established REITs depending on sector, geography, and growth profile. NAV-based valuation lets investors compare the REIT's market cap to the underlying real-estate value, with NAV discounts and premiums signaling investor sentiment on management's value-creation track record.

Asset Managers: P/E Plus P/AUM

Asset managers value on P/E plus price-to-AUM (typically 1 to 3 percent of AUM for traditional managers, 5 to 10 percent for alternative managers). The hybrid framework reflects both the earnings stream and the underlying asset base that produces fees, and asset-manager IPOs require both anchors.

Energy: EV/EBITDA Plus Reserve-Based Multiples

Energy E&P issuers value on EV/EBITDA cross-checked with reserve-based multiples (EV per proved reserves, EV per flowing barrel-of-oil-equivalent). The reserve-based metrics handle the sector's depletion economics and reserve-replacement dynamics that EBITDA alone does not capture.

Issuers with multiple distinct business lines (especially carve-outs from a parent and conglomerate IPOs) require a sum-of-the-parts approach rather than a single peer-multiple application. The bank values each segment separately using the multiples and peer set most relevant to that segment, then aggregates to a total enterprise value.

When SOTP Applies

SOTP is the appropriate methodology when the issuer's segments would warrant materially different multiples (a software segment at 25-30x EBITDA plus an industrial segment at 12-14x EBITDA cannot defensibly be valued on either single multiple). Recent precedent IPOs and carve-outs that used SOTP-driven valuation include Kenvue (Johnson & Johnson's consumer health spin-off, May 2023 IPO at $22 per share, $41 billion valuation, the largest US IPO since Rivian), Solventum (3M's healthcare carve-out, NYSE: SOLV, listed April 1, 2024), and GE Vernova (GE's energy carve-out, listed April 2, 2024 alongside the GE Aerospace separation; GE HealthCare had already begun trading separately on Nasdaq in January 2023, and combined market value of all three GE successors now exceeds 4x the pre-2022 GE).

Construction Mechanics

The analysis runs in five steps:

The principal judgment calls are peer-set selection (which always produces investor pushback during marketing) and the size of any conglomerate or holding-company discount.

Conglomerate Discount

Diversified companies typically trade at 10-25 percent discounts to their break-up SOTP value due to perceived management inefficiency, lack of focus, information opacity, and capital-allocation cross-subsidization. ECM bankers running an IPO on a multi-segment issuer must explicitly bridge from the SOTP value to the IPO valuation: the IPO discount is layered on top of any conglomerate-discount adjustment, with the combined effect typically producing IPO valuations 20-35 percent below the unbiased SOTP estimate. The 2024-2026 wave of industrial carve-out IPOs (GE Vernova, Solventum, others) reflects in part the structural value-creation thesis that SOTP captures and the public markets have validated post-listing.

ECM bankers rarely rely on a single multiple. The standard practice is to triangulate across multiple metrics to produce a defensible range.

The Standard Triangulation

The four anchors together produce a triangulated valuation range, with the ECM banker's recommendation typically falling near the midpoint of the consensus across methodologies.

When the Multiples Diverge

Multiples diverge when the issuer's profile differs materially from the peer set on a specific dimension. A SaaS issuer with higher growth than the peer set might trade at a higher EV/Revenue multiple but lower EV/EBITDA multiple (because it is investing more aggressively in growth, suppressing near-term EBITDA). The divergence is informative: it tells the banker which dimension of the issuer's profile the market is most likely to weight when pricing the deal.

The DCF as Discipline

The DCF cross-check is principally a discipline tool. If the trading-multiple analysis produces a valuation that the DCF cannot support at any reasonable terminal-value assumption, the trading multiples are pricing in growth or margin expansion the underlying cash flows do not support, and the IPO range needs to be reconsidered.

The mechanical process by which an ECM banker builds the multiple analysis is recognizable across deals. The two principal arithmetic steps are applying the multiple to the issuer's metric to produce implied enterprise value, and then walking from EV to equity value:

(equivalently, EV less net debt and other non-equity claims). Per-share offering price then divides equity value by total post-IPO shares outstanding.

ECM bankers must also choose between forward (next 12 months) and LTM (last 12 months) multiples, and the choice can materially affect the valuation outcome.

Forward as the Default Anchor

ECM IPO valuations typically use forward multiples (NTM revenue, NTM EBITDA) rather than LTM multiples because investors price expected future performance rather than historical results. For a metric growing at rate $g$, the forward multiple is the LTM multiple scaled down by the growth factor:

The forward orientation is particularly important for high-growth issuers where the LTM-to-forward growth rate is meaningful: a 50 percent growth issuer trading at 8x LTM revenue trades at 5.3x NTM revenue (8 / 1.5), materially different valuation outcomes from the same multiple framework. For larger commercial-stage biotech and pharma issuers, NTM P/E is the standard anchor; for earlier-stage biotech with valuable products that are not yet launched or are in early launch, bankers extend to longer-term forward P/E or discounted forward P/E to capture the post-launch earnings stream the market is pricing.

When LTM Matters

LTM multiples come into play for sanity-checking and for issuers where forward visibility is limited (cyclical industrials, commodity producers, early-cycle businesses). Standard practice presents both LTM and NTM multiples, with the working group selecting the primary anchor based on which produces the cleaner peer-comparable analysis. Forward multiples beyond NTM (forward 24-month or longer) appear in some high-growth issuer presentations but are typically reserved for cross-checks rather than primary anchors because the further-forward projections are less defensible.

EV/Revenue with a Rule of 40 lens for SaaS, EV/EBITDA for established profitable issuers, P/E plus P/B for banks, rNPV for pre-revenue biotech, and SOTP for any multi-segment business: that is the multiple-selection map every ECM analyst loads at the start of a mandate. The next article zooms in on the prior step, peer set selection and the DCF cross-check, since the multiple framework is only as defensible as the comparables it sits on.